Gå direkt till innehåll
The image is a montage featuring the MucoLife Therapeutics team.
The image is a montage featuring the MucoLife Therapeutics team.

Pressmeddelande —

MucoLife Therapeutics receives SEK 1 million from Vinnova to scale up manufacturing of mucus-targeting therapy for COPD

..............................................................

GU Ventures shares news and information about its operations, portfolio companies, and alumni companies:

..............................................................


MucoLife Therapeutics AB has been granted SEK 1 million by Vinnova, Sweden’s innovation agency, in the call “Support to small and medium-sized companies for the use of life science infrastructure.” The funding supports establishing a scalable manufacturing process for MLT-001, the company’s first-in-class inhaled peptide designed to dissolve airway mucus plugs in chronic obstructive pulmonary disease (COPD).

Mucus plugging is present in more than half of patients with moderate-to-severe COPD, and no approved therapy targets it directly. Mucus obstruction is a relevant disease feature associated with poor outcomes, including reduced lung function, more exacerbations and increased mortality, and they can be targeted for the benefit of patients. MucoLife’s work has shown that the synthesis of MLT-001 is scalable, and the grant will be used to develop the process of scaled-up manufacturing.

The development will be carried out in close collaboration with a contract development and manufacturing organization (CDMO) partner and aims to establish a process that reaches a suitable level of purity at a documented yield. The project will also deliver a transferable process description and control strategy for later Good Manufacturing Practice (GMP) manufacture.

“Manufacturing is the step that turns a promising molecule into a medicine,” says Thaher Pelaseyed, CEO of MucoLife. “With Vinnova’s support, we can build the purification process for MLT-001 and move closer to clinical trials.”

About MucoLife Therapeutics
MucoLife is a Gothenburg-based biopharmaceutical company developing MLT-001, a first-in-class inhaled mucus modulator for COPD and other muco-obstructive lung diseases. MLT-001 is an investigational, preclinical compound.

Press contact, MucoLife Therapeutics:

Thaher Pelaseyed, PhD
CEO
MucoLife Therapeutics
tpelaseyed@mucolife.com
+46 733 79 43 47


For more information, kindly go to: https://mucolife.com/

Ämnen

Kategorier

Regioner


Om GU Ventures AB

GU Ventures bygger företag av banbrytande idéer som kan forma en bättre morgondag och är topprankad av UBI Global Index som en av världens 20 ledande universitetsdrivna inkubatorer. Vi finansierar och utvecklar nya innovativa affärsidéer med kopplingar till Göteborgs universitet, som är ett av norra Europas största universitet. Vårt uppdrag är att kommersialisera dessa innovationer, så att det leder till användning av forskning och kompetens, förnyelse av näringslivet, skapande av jobb och hållbar tillväxt. Vårt passionerade team av företagsbyggare, finansexperter, IP och juridisk talang supporterar dedikerat våra företag och säkerställer deras framgång.

Sedan startpunkten 1995 har GU Ventures utvecklat över 200 nya företag, varav 15 har blivit listade. Vår portfölj består av 100-tal innehav och ett antal projekt.

I den senaste undersökningen matchar 87% av företagen de globala hållbarhetsmål som ställts av FN. GU Ventures ägs helt av den svenska staten och förvaltas av Göteborgs universitet. Läs gärna mer på: www.guventures.com.

Kontakter